NEW YORK |
NEW YORK (Reuters) – Novartis AG pronounced on Thursday it is recalling 183 lots of cough syrup after finding a child-resistant underline on some bottle caps was not functioning correctly.
The Swiss drug association is recalling 142 lots of Triaminic and 41 lots of Theraflu Warming Relief Syrups made in a United States before Dec 2011.
The association pronounced it perceived 4 reports of random ingestion of a Triaminic syrup. One studious compulsory medical courtesy though recovered.
No inauspicious affects were reported with a Theraflu syrup, though a product is being removed since it has a same top as a malfunctioning Triaminic bottles.
The influenced cough syrup bottles were constructed during Novartis’ Lincoln, Nebraska, production facility. A consumer censure final Nov triggered an inner review that led a association to emanate a recall.
Julie Masow, a mouthpiece for Novartis, pronounced 97 percent of a product in doubt has possibly been used or already returned.
Manufacturing during a Lincoln, Nebraska, trickery was dangling in Dec 2011 and has nonetheless to reopen, Masow said.
(Reporting By Adam Kerlin; modifying by Carol Bishopric)
